Morphotek is actively seeking partnerships with leading corporations, research organizations, and academic centers of excellence to identify and accelerate the discovery and development of new products. We have entered into multiple strategic collaborations with leading companies in diverse industries and with academic research organizations to gain access to and optimize products for potential future commercial use. In addition, the company is employing its technology for military and Homeland Security initiatives to develop proprietary molecules for the detection and treatment of pathogenic organisms used in biological warfare.

Partnership News

March 31, 2016

Morphotek and AREVA Med to collaborate on Lead-212 Targeted Alpha Therapies
Read More

February 3, 2016

Morphotek Announces Collaboration with Mayo Clinic
Read More

December 16, 2015

Morphotek, Inc. Announces an Agreement With Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Mesothelin in Malignant Tissues
Read More

December 3, 2015

Morphotek Announces Collaboration Agreement with University of Wisconsin-Madison to Study the Immunosuppressive Effects of CA125 Tumor Antigen on Immune-Based Therapies for Ovarian Cancer
Read More

November 17, 2015

Morphotek Announces Collaboration Agreement With University of Gothenburg to Develop Farletuzumab, an Investigational Anti-Folate Receptor Alpha Monoclonal Antibody, for Alpha-Particle Radioimmunotherapy in Ovarian Cancer
Read More

November 9, 2015

Morphotek, Inc. Announces a License Agreement With Blaze Bioscience Inc. For The Development of Novel Oncology Imaging Technology
Read More

March 20, 2012

Biocare Medical Launches Key Diagnostic Kit to Identify Folate Receptor Alpha Expression
Read More

January 9, 2012

Morphotek Enters Into Agreements With Fox Chase Cancer Center to Acquire Clinical Samples for the Development and Validation of Companion Diagnostic Kits
Read More

November 17, 2010

Morphotek, Inc. Announces Initiation of A Sponsored Research Agreement with Hokkaido University to Evaluate Amatuximab (MORAb-009) in Advanced Pancreatic Cancer
Read More

March 25, 2009

Human Genome Sciences and Morphotek, Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
Read More

Displaying results 1-10 (of 12)
 |<  < 1 - 2  >  >|